Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay ...

It had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs) ...

Bristol-Myers Squibb Company (NYSE:BMY) ranks sixth on our list of the best dividend stocks for the long term, according to ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

Henlius is developing its own proposed biosimilar of ipilimumab in an integrated Phase I/III trial in the unresectable hepatocellular carcinoma setting, targeting 656 patients to be enrolled ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Verizon’s 5G growth and Bristol Myers Squibb’s innovation both provide strong income and growth prospects. Read more on BMY ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American ...